Hansa Biopharma AB (publ) (0RC7.IL)

27,15 +0,02 (+0,07%) Alla chiusura: 05:51PM BST

Hansa Biopharma AB (publ)

ScheelevAegen 22
Lund 223 63
Sweden
46 46 16 56 70
https://www.hansabiopharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 162

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Søren Tulstrup M.Sc	Pres & CEO	15,26M	N/D	1965
Mr. Donato Spota	CFO & Sr. VP	N/D	N/D	1971
Dr. Christian Kjellman	Sr. VP, Chief Scientific Officer & COO	N/D	N/D	1967
Ms. Eva-Maria Joed	VP of Fin. & Admin.	N/D	N/D	1969
Mr. Klaus Sindahl	VP & Head of Investor Relations	N/D	N/D	N/D
Ms. Anne Säfström Lanner	Sr. VP & Chief HR Officer	N/D	N/D	1969
Mr. Emanuel Björne	VP & Head of Bus. Devel.	N/D	N/D	1973
Dr. Lena Winstedt	Head of Science	N/D	N/D	1969
Ms. Vincenza Nigro M.B.A.	VP & Head of Medical Affairs	N/D	N/D	N/D
Dr. Achim Kaufhold M.D., Ph.D.	Sr. VP & Chief Medical Officer	N/D	N/D	1958

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Hansa Biopharma AB (publ) al 1 ottobre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.